Darren R. Hodgson PhD

Darren Hodgson, Ph.D. is a senior principal translational scientist and project leader for the bladder cancer umbrella study IMED Oncology, AstraZeneca, having previously had positions in global medicine develop­ment, academia, biotechnology, and diagnostics sectors. Dr. Hodgson has over 7 years of experience as a core member of a multi-functional global product team and has been responsible for strategy, internal and external assay development, clinical deployment, and regulatory representation for bio­markers used as primary, secondary, and exploratory objectives of clinical studies in all stages of drug development.

Most recently, Dr. Hodgson was the translational science lead for Lynparza, which is AstraZeneca’s first-in-class PARP inhibitor approved in 2014. This was used for ovarian cancer indications in Europe and the US, which is defined by loss of function mutations in tumor suppressor genes. Dr. Hodgson is the author of numerous reviews, original patents and papers, journal editor, the chairman of the Manchester Consumer Healthcare Ethics committee, and lectures at the Universities of Manchester and Leeds.